A 30-month prospective study on the treatment of retinoblastoma in the Gabriel Toure Teaching Hospital, Bamako, Mali

Togo, Boubacar; Sylla, Fatou K.; Traoré, Fousseyni; Sylla, Mariam; Dicko-Traoré, Fatoumata; Toumani, Sidibé; Diakite, A.; Marouf, Keïta Mamadou

doi:10.1136/bjo.2009.159699

Cited by 47 publications

(44 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This pattern of parents not accepting the enucleation of the affected eye or defaulting from follow-up after a conservative intent is similar in many areas of the developing world. Rates from 18% to 50% have been reported by groups in from Asia, Africa, and Central America [11,13,21,26,29,33]. Decisions against enucleating the second affected eye after conservative treatment fails account for a survival rate of less than 60% in patients with bilateral retinoblastoma in Taiwan, a relatively affluent country having a national healthcare program that offers subsidized care [34].…”

Section: Strategies For Earlier Diagnosis and For Improving Treatmentmentioning

confidence: 99%

“…In contrast, in most MICs, metastatic disease is present at diagnosis in less than 10% of the cases [7,22,23]. Treatment with neoadjuvant chemotherapy, followed by secondary enucleation and adjuvant therapy is the current approach in most centers [13,40,41]. Encouraging results have been reported for the treatment of retinoblastoma that is disseminated to the orbit or the preauricular lymph nodes has resulted in disease-free survival rates over 70% [41].…”

Section: Treating Patients With Overt Extraocular Diseasementioning

confidence: 99%

“…Retinoblastoma is usually one of the more common malignancies in pediatric oncology services in developing countries [13] and recent evidence from population-based studies showed an increased incidence of retinoblastoma in some countries compared to western countries [1,14]. Data from national and regional registries confirmed an increased incidence of retinoblastoma in some areas of Brazil [15] and Mexico [16], where the incidence of retinoblastoma is as high as three to seven times that of Western Europe [14].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Strategies to manage retinoblastoma in developing countries

Chantada

Qaddoumi

Canturk³

et al. 2010

Pediatric Blood & Cancer

131

109

View full text Add to dashboard Cite

Survival of retinoblastoma is >90% in developed countries but there are significant differences with developing countries in stage at presentation, available treatment options, family compliance, and survival. In low‐income countries (LICs), children present with advanced disease, and the reasons are socioeconomic and cultural. In middle‐income countries (MICs), survival rates are better (>70%), but there is a high prevalence of microscopically disseminated extraocular disease. Programs for eye preservation have been developed, but toxicity‐related mortality is higher. Although effective treatment of microscopically extraocular disease improved the outcome, worldwide survival will be increased only by earlier diagnosis and better treatment adherence. Pediatr Blood Cancer 2011;56:341–348. © 2010 Wiley‐Liss, Inc.

show abstract

Section: Strategies For Earlier Diagnosis and For Improving Treatmentmentioning

confidence: 99%

Section: Treating Patients With Overt Extraocular Diseasementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Strategies to manage retinoblastoma in developing countries

Chantada

Qaddoumi

Canturk³

et al. 2010

Pediatric Blood & Cancer

131

109

View full text Add to dashboard Cite

show abstract

“…On the other extreme, presentations of retinoblastoma differ. From Sudan 9 , buphthalmos (56%) and leukocoria (32%) were most common, and from Mali in Africa 10 , proptosis (55%), leukocoria (38%), strabismus (6%), and buphthalmos (2%) were found. Efforts are underway internationally to educate clinicians, nurses, patients, and entire populations for improvement in retinoblastoma detection.…”

Section: Clinical Features Of Retinoblastomamentioning

confidence: 99%

“…Enucleation continues to remain critical for advanced retinoblastoma, particularly in Asia and Africa. 3,10,11 In the 1980s, external beam radiotherapy (EBRT) was popular, but later-realized risks of radiationrelated second cancers have lead to reduction in use of this modality. In the 1990s, systemic IVC was introduced with agents of vincristine, etoposide, and carboplatin (VEC).…”

Section: Management Of Retinoblastoma: General Conceptsmentioning

confidence: 99%

Erratum: Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy

Shields¹,

Fulco²,

Arias³

et al. 2012

Eye

View full text Add to dashboard Cite

In this report, we explore retinoblastoma diagnostic accuracy and review chemotherapy alternatives for retinoblastoma using intravenous, intra-arterial, periocular, and intravitreal routes. A review of 2775 patients referred for management of retinoblastoma, disclosed 78% with confirmed retinoblastoma and 22% with simulating lesions, termed pseudoretinoblastomas. Children r2 years old showed leading pseudoretinoblastomas of persistent fetal vasculature, Coats disease, and vitreous haemorrhage, whereas those 45 years showed simulators of Coats, toxocariasis, and familial exudative vitreoretinopathy. The diagnosis of retinoblastoma should be established before planning therapeutic strategy. Chemotherapy strategy depends on tumour laterality and stage of disease. If bilateral retinoblastoma, intravenous chemotherapy (IVC) is important as first-line therapy for control of intraocular disease, prevention of metastasis, and reduction in prevalence of pinealoblastoma and long-term second malignant neoplasms. Bilateral groups D and E retinoblastoma receive additional subtenon's carboplatin boost for improved local control. If unilateral disease is present, then intra-arterial chemotherapy (IAC) is often considered. IAC can be salvage therapy following chemoreduction failure. Unilateral retinoblastoma of groups D and E are managed with enucleation or globeconserving IVC and/or IAC. Intravitreal chemotherapy is cautiously reserved for recurrent vitreous seeds following other therapies. In conclusion, the strategy for retinoblastoma management with chemotherapy depends on tumour laterality and stage of disease. Bilateral retinoblastoma is most often managed with IVC and unilateral retinoblastoma with IAC, but if advanced stage, combination IVC plus IAC or enucleation.

show abstract

Treatment adherence in retinoblastoma: A retro‐prospective cohort study in Ivory Coast and the Democratic Republic of Congo

Lukamba,

Budiongo,

Monga

et al. 2023

Cancer Reports

View full text Add to dashboard Cite

BackgroundIn high‐income countries, retinoblastoma is curable in more than 95% of cases, whereas in low‐income countries, mortality remains high, especially when the diagnosis is made late or the treatment is discontinued.AimsTo determine the factors associated with adherence to the treatment of retinoblastoma in the Ivory Coast and the Democratic Republic of Congo (DRC).Methods and ResultsA retro‐prospective cohort study was carried out. Data were collected from patient folders and follow‐up records of parents.ResultsA total of 175 children with retinoblastoma were registered from January 2013 to December 2015. Seventy‐six children (43%) were 5 years old and above. Care costs were covered by families in 86.9% of cases. Chemotherapy refusal was recorded in 39 cases (22.3%), and enucleation refusal was recorded in 79 cases (45.1%). After 36 months of follow‐up, we recorded 16.6% deaths, 27.4% treatment dropouts, and 18.3% loss to follow‐up after treatment. The commonest cause for enucleation refusal was fear of infirmity, while chemotherapy refusal and absconding treatment were due to financial constraints.ConclusionPoor adherence to retinoblastoma management was due to financial constraints, and a lack of knowledge of the disease and its treatment. Family psychosocial support is needed to improve this condition.

show abstract

A 30-month prospective study on the treatment of retinoblastoma in the Gabriel Toure Teaching Hospital, Bamako, Mali

Cited by 47 publications

References 13 publications

Strategies to manage retinoblastoma in developing countries

Strategies to manage retinoblastoma in developing countries

Erratum: Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy

Treatment adherence in retinoblastoma: A retro‐prospective cohort study in Ivory Coast and the Democratic Republic of Congo

Contact Info

Product

Resources

About